Aaron Gorovitz - 21 Oct 2022 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)

Reporting relationship: Director
Issuer ticker: NRXP
Reported as of: 21 Oct 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Nov 2022, 16:46:27 UTC
Prior SEC filing: 10 Jun 2021
Next SEC filing: 11 Sep 2023
Source filing: View source filing
Reporting owner signature: /s/ Aaron Gorovitz

Key filing fact

Aaron Gorovitz filed Form 4 for NRX Pharmaceuticals, Inc. (NRXP) on 22 Nov 2022.

Key facts

This page summarizes Aaron Gorovitz's Form 4 filing for NRX Pharmaceuticals, Inc. (NRXP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Nov 2022, 16:46.

Change

Previous filing in this sequence was filed on 10 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRXP transaction Derivative

Employee Stock Option

Award

Transaction value
Shares: +162,660
Change %
Price
Shares after: 162,660
Date: 21 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 162,660
Exercise price: $0.7500
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc.